Tumor Immune Syngeneic MOuse (TISMO) is a database specifically designed for hosting, visualizing, and analyzing an extensive collection of syngeneic mouse model data. We uniformly processed raw sequencing data for 1,518 mouse samples, covering 68 cell lines and 19 cancer types, to generate gene expression and immune cell infiltration profiles, of which 832 were from immune checkpoint blockade (ICB) studies. In addition, TISMO hosts 605 in vitro samples of which 195 were cytokine treated. Sample metadata, including cancer type, cell line, mouse strain, transplantation site, ICB treatment, and response status were manually curated. TISMO provides interactive interfaces for users to explore gene expression and immune infiltration, and allows systematic comparisons between different model characteristics, and treatment and response groups.Get started by exploring:
Zexian Zeng*#, Cheryl J Wong*, Lin Yang*, Nofal Ouardaoui, Dian Li, Wubing Zhang, Shengqing Gu, Yi Zhang, Yang Liu, Xiaoqing Wang, Jingxin Fu, Liye Zhou, Boning Zhang, Sarah Kim, Kathleen B Yates, Myles Brown, Gordon J Freeman, Ravindra Uppaluri, Robert Manguso, X Shirley Liu#. TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Research 2021 [DOI] [PubMed]
X Shirley Liu: firstname.lastname@example.org
TISMO | © X Shirley Liu Lab 2021 | Dana Farber Cancer Institute
An overview of the syngeneic mouse model data in the TISMO database. TISMO contains 605 in vitro RNA-seq samples from 49 syngeneic cancer cell lines across 23 cancer types, of which 195 underwent cytokine treatment. TISMO also includes 1,518 in vivo RNA-seq samples from 68 syngeneic mouse tumor models across 19 cancer types, of which 832 were from immune checkpoint blockade (ICB) studies. The ‘ICB Treatment’ tab summarizes tumor samples treated with immune-checkpoint blockade such as anti-PD1, anti-PDL1, anti-PDL2, antiCTLA4, and anti-CTLA4 + anti-PD1/L1 combinations. The ‘Cytokine Treatment’ tab summarizes in vitro tumor lines treated with cytokines such as interferon γ (IFNγ), IFNβ, tumor necrosis factor alpha (TNFα) and transforming growth factor (TNFβ). The ‘Baseline’ tab summarizes in vivo and in vitro samples used as study controls (e.g. untreated, isotype or vehicle treated).
We have collected available survival information from published studies. Survival information is available in 32% of ICB-related samples and 24% of total in vivo tumor samples in TISMO.